文献速递血栓与止血

中度血友病A患者中的凝血因子VIII K1693N突变(FVIII-Nara)通过涉及P4'位点导致对凝血酶在Arg1689处切割的抵抗

The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.
PubMed 文献 · J Thromb Haemost · 2025-05-13

本文报道一例中度血友病A患者携带新型FVIII天然突变K1693N(FVIII:C/FVIII:Ag = 1.9 IU/dL/124 IU/dL),表现为交叉反应物质阳性。体外表达研究表明,K1693N突变延迟凝血酶在Arg1689处的切割并降低峰值FVIII:C,提示P4'位点天冬酰胺取代介导凝血酶抵抗。

要点

  • FVIII-K1693N突变患者表现为FVIII:C/FVIII:Ag = 1.9 IU/dL/124 IU/dL,分类为交叉反应物质阳性。
  • FVIII-K1693N在凝血酶激活后显示Arg1689处切割延迟和峰值FVIII:C降低。
  • P4'位点Lys1693和Lys376通过不同机制影响FVIII功能。

核心结论

  • 位于P4'位点的Lys1693和Lys376被提示通过不同机制影响FVIII功能,表明患者来源的突变可揭示FVIII激活的功能方面。

研究设计与样本

  • 对FVIII-K1693N及其比较变体K1693A、以及FVIII-K376N及其比较变体K376A进行凝血酶介导激活分析,所有突变体在BHK细胞中表达。

主要发现

  • FVIII-K1693N显示Arg1689处切割延迟和峰值FVIII:C降低,而FVIII-K1693A在凝血酶激活后显示FVIII:C轻度降低。
  • FVIII-K1693A突变在凝血酶激活后显示峰值FVIII:C轻度降低且切割与野生型相似。
  • FVIII-K376N和FVIII-K376A的FVIII比活性分别为野生型的6.1%/3.1%(一期法)。
  • 两种K376突变体的凝血酶催化Arg372处切割与野生型相当,但凝血酶催化的FVIII激活严重受抑。
  • FVIII-K376N(k = 0.53)和FVIII-K376A(k = 0.99)的FVIIIa活性自发衰减率高于野生型(k = 0.32)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some patients with nonsevere hemophilia A (HA) are diagnosed with reduced factor (F)VIII activity (FVIII:C) relative to FVIII antigen (FVIII:Ag) and are classified as cross-reactive material-positive. We previously found a novel FVIII-Lys1693Asn (K1693N) natural mutation in a patient with HA with moderate phenotype (FVIII:C/FVIII:Ag = 1.9 IU/dL/124 IU/dL). OBJECTIVE: To examine the mechanism(s) involving the P4' site on thrombin cleavage site at Arg1689 in a cross-reactive material-positive phenotype. METHODS: FVIII-K1693N and its comparison variant K1693A were analyzed for t thrombin-mediated activation. FVIII-K376N, listed in the HA database due to a similar Lys-to-Asn substitution, was examined with K376A as its comparison. All mutants were expressed in BHK cells. RESULTS: FVIII-K1693N showed delayed cleavage at Arg1689 and low peak FVIII:C, while FVIII-K1693A showed mildly reduced FVIII:C after thrombin activation. Mildly reduced peak FVIII:C and similar cleavage to wild-type was illustrated, however, with the FVIII-K1693A mutation after thrombin activation. These findings indicated that the conversion to Asn at P4' site mediated thrombin resistance. FVIII specific activities of FVIII-K376N and FVIII-K376A were 6.1%/3.1% (one-stage assay) of wild-type, respectively. Thrombin-catalyzed cleavage at Arg372 was comparable to wild-type with both mutants, but thrombin-catalyzed FVIII activation was severely-depressed. Spontaneous decay rates of FVIIIa activity with FVIII-K376N (k = 0.53) and FVIII-K376A (k = 0.99) were greater compared to wild-type (k = 0.32), suggesting that cleavage of P4' site following cleavage at Arg372contributed to A1-A2 domainal interaction. CONCLUSION: Lys1693 and Lys376, both located at P4' sites, are suggested to influence FVIII function via distinct mechanisms, indicating that patient-derived mutations can reveal functional aspects of FVIII activation.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Furukawa S, Baatartsogt N, Kawamura T, et al. The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position. J Thromb Haemost. 2025. PMID: 40374115. doi:10.1016/j.jtha.2025.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。